Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 3.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -1.08M | -3.53M | -3.49M | -8.96M | -4.45M | -1.39M |
EBITDA | -365.68M | -113.39M | -114.37M | -90.89M | -67.58M | -41.95M |
Net Income | -1.66B | -116.91M | -117.86M | -90.77M | -68.78M | -43.34M |
Balance Sheet | ||||||
Total Assets | 205.37M | 142.89M | 198.13M | 299.37M | 242.59M | 75.91M |
Cash, Cash Equivalents and Short-Term Investments | 200.56M | 91.93M | 137.18M | 230.25M | 207.47M | 48.54M |
Total Debt | 0.00 | 31.83M | 35.66M | 38.91M | 18.01M | 18.29M |
Total Liabilities | 1.71B | 46.23M | 47.40M | 48.76M | 26.33M | 27.64M |
Stockholders Equity | -1.51B | 96.66M | 150.72M | 250.61M | 216.26M | 48.27M |
Cash Flow | ||||||
Free Cash Flow | -114.09M | -99.89M | -101.36M | -93.61M | -73.04M | -40.45M |
Operating Cash Flow | -113.60M | -99.66M | -100.29M | -85.14M | -69.14M | -36.29M |
Investing Cash Flow | 310.00K | 96.86M | 71.01M | -94.09M | -91.65M | -4.16M |
Financing Cash Flow | 227.79M | 53.39M | 2.94M | 117.14M | 232.91M | 82.53M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $190.03M | ― | -52.99% | ― | 16.55% | 16.73% | |
51 Neutral | $7.91B | -0.36 | -41.71% | 2.23% | 23.45% | -1.86% | |
47 Neutral | $91.79M | ― | 149.62% | ― | -5.22% | 82.06% | |
47 Neutral | $36.10M | ― | -169.54% | ― | -100.00% | 29.21% | |
46 Neutral | $124.07M | ― | -49.55% | ― | -33.76% | 17.10% | |
37 Underperform | $102.83M | ― | -67.55% | ― | ― | -9.87% | |
33 Underperform | $244.50M | ― | -125.43% | ― | ― | -686.13% |
On March 31, 2025, Eyal C. Attar, M.D., announced his resignation as Chief Medical Officer of Vor Biopharma Inc., effective April 18, 2025, to pursue a new opportunity. Vor Biopharma plans to enter into a consulting agreement with Dr. Attar for transition services, acknowledging his contributions to the company.
On February 3, 2025, Vor Biopharma’s board approved a stock option repricing to reduce the exercise price of certain options to $1.34 per share, impacting approximately 6.76 million shares. This move aims to motivate and retain employees while avoiding stock dilution or additional cash outlays, with a retention period set until February 3, 2026 or earlier under specific conditions.